@article{b60d912681314f1d84d4ba56b37bd500,
title = "The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms",
abstract = "High blood levels of soluble urokinase Plasminogen Activator Receptor (suPAR) are associated with poor outcomes in human immunodeficiency-1 (HIV-1) infected individuals. Research on the clinical value of suPAR in HIV-1 infection led to the development of the suPARnostic(R) assay for commercial use in 2006. The aim of this study was to: 1) Evaluate the prognostic value of the new suPARnostic assay and 2) Determine whether polymorphisms in the active promoter of uPAR influences survival and/or suPAR values in HIV-1 patients who are antiretroviral therapy (ART) naive.",
keywords = "Adult, Antiretroviral Therapy, Highly Active, Biological Markers, Case-Control Studies, DNA, Viral, Denmark, Enzyme-Linked Immunosorbent Assay, Female, HIV Infections, HIV-1, Humans, Kaplan-Meier Estimate, Male, Polymorphism, Genetic, Polymorphism, Restriction Fragment Length, Predictive Value of Tests, Probability, Prognosis, Promoter Regions, Genetic, Receptors, Cell Surface, Receptors, Urokinase Plasminogen Activator, Retrospective Studies, Risk Assessment, Sensitivity and Specificity, Statistics, Nonparametric, Survival Analysis",
author = "Schneider, {Uffe V} and Rikke Nielsen and Court Pedersen and Jesper Eugen-Olsen",
year = "2007",
doi = "10.1186/1471-2334-7-134",
language = "English",
volume = "7",
pages = "134",
journal = "BMC Infectious Disease",
publisher = "BioMed Central Ltd",
number = "1",
}